p450 - publications

Predict more p450 - ligand interactions now!



Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.


Pharmacogenomics J. 2013 Apr 2;


Authors: Brandl EJ, Tiwari AK, Zhou X, Deluce J, Kennedy JL, Müller DJ, Richter MA


Abstract

Numerous studies have reported on pharmacogenetics of antidepressant response in depression. In contrast, little is known of response predictors in obsessive-compulsive disorder (OCD), a disorder with among the lowest proportion of responders to medication (40-60%). Our study is the largest investigation to date (N=184) of treatment response and side effects to antidepressants in OCD based on metabolizer status for CYP2D6 and CYP2C19. We observed significantly more failed medication trials in CYP2D6 non-extensive compared with extensive metabolizers (P=0.007). CYP2D6 metabolizer status was associated with side effects to venlafaxine (P=0.022). There were nonsignificant trends for association of CYP2D6 metabolizer status with response to fluoxetine (P=0.056) and of CYP2C19 metabolizer status with response to sertraline (P=0.064). Our study is the first to indicate that CYP genes may have a role in antidepressant response in OCD. More research is required for a future clinical application of genetic testing, which could lead to improved treatment outcomes.The Pharmacogenomics Journal advance online publication, 2 April 2013; doi:10.1038/tpj.2013.12.

PMID: 23545896 [PubMed - as supplied by publisher]